Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease

被引:27
|
作者
Jakobsson, Jonas K. F. [1 ]
Aaltonen, H. Laura [2 ]
Nicklasson, Hanna [2 ]
Gudmundsson, Anders [1 ]
Rissler, Jenny [1 ,3 ]
Wollmer, Per [2 ]
Londahl, Jakob [1 ]
机构
[1] Lund Univ, Div Ergon & Aerosol Technol, Lund, Sweden
[2] Lund Univ, Dept Translat Med, Malmo, Sweden
[3] SP Tech Res Inst Sweden, Chem Mat & Surfaces, Lund, Sweden
来源
BMC PULMONARY MEDICINE | 2018年 / 18卷
基金
瑞典研究理事会;
关键词
Lung deposition; Nanoparticles; Emphysema; Chronic obstructive pulmonary disease; Inhalation exposure; Human; In vivo study; HUMAN RESPIRATORY-TRACT; AEROSOL BOLUS DISPERSION; ULTRAFINE PARTICLE DEPOSITION; ENVIRONMENTAL TOBACCO-SMOKE; AIRWAY MORPHOMETRY; LUNG EMPHYSEMA; AIRBORNE NANOPARTICLES; BIOLOGICAL VARIABILITY; PERIPHERAL AIRWAYS; BREATHING PATTERNS;
D O I
10.1186/s12890-018-0697-2
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Respiratory tract deposition of airborne particles is a key link to understand their health impact. Experimental data are limited for vulnerable groups such as individuals with respiratory diseases. The aim of this study is to investigate the differences in lung deposition of nanoparticles in the distal lung for healthy subjects and subjects with respiratory disease. Methods: Lung deposition of nanoparticles (50 and 100 nm) was measured after a 10 s breath-hold for three groups: healthy never-smoking subjects (n = 17), asymptomatic (active and former) smokers (n = 15) and subjects with chronic obstructive pulmonary disease (n = 16). Measurements were made at 1300 mL and 1800 mL volumetric lung depth. Each subject also underwent conventional lung function tests, including post bronchodilator FEV1, VC, and diffusing capacity for carbon monoxide, D-L,D-CO. Patients with previously diagnosed respiratory disease underwent a CT-scan of the lungs. Particle lung deposition fraction, was compared between the groups and with conventional lung function tests. Results: We found that the deposition fraction was significantly lower for subjects with emphysema compared to the other subjects (p = 0.001-0.01), but no significant differences were found between healthy never-smokers and smokers. Furthermore, the particle deposition correlated with pulmonary function tests, FEV1%pred (p < 0.05), FEV1NC%pred (p < 0.01) and D-L,D-CO (p < 0.0005) when all subjects were included. Furthermore, for subjects with emphysema, deposition fraction correlated strongly with D-L,D-CO (Pearson's r= 0.80-0.85, p < 0.002) while this correlation was not found within the other groups. Conclusions: Lower deposition fraction was observed for emphysematous subjects and this can be explained by enlarged distal airspaces in the lungs. As expected, deposition increases for smaller particles and deeper inhalation. The observed results have implications for exposure assessment of air pollution and dosimetry of aerosol-based drug delivery of nanoparticles.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease
    Jonas K F Jakobsson
    H Laura Aaltonen
    Hanna Nicklasson
    Anders Gudmundsson
    Jenny Rissler
    Per Wollmer
    Jakob Löndahl
    BMC Pulmonary Medicine, 18
  • [2] Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History
    Melani, Andrea S.
    Croce, Sara
    Fabbri, Gaia
    Messina, Maddalena
    Bargagli, Elena
    BIOMOLECULES, 2024, 14 (02)
  • [3] Inhaled corticosteroids and chronic obstructive pulmonary disease
    Sapey, E
    Langford, NJ
    Kendall, MJ
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (04) : 235 - 238
  • [4] Inhaled corticosteroids for chronic obstructive pulmonary disease
    Cazzola, Mario
    Rogliani, Paola
    Novelli, Lucia
    Matera, Maria Gabriella
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (18) : 2489 - 2499
  • [5] Inhaled Anticholinergics for Chronic Obstructive Pulmonary Disease
    Singh, Sonal
    Furberg, Curt D.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (10) : 920 - 922
  • [6] Inhaled corticosteroids for chronic obstructive pulmonary disease
    Park, Hye Yun
    Man, S. F. Paul
    Sin, Don D.
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [7] Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
    Siederer, Sarah
    Allen, Ann
    Yang, Shuying
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (06) : 743 - 758
  • [8] Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
    Sarah Siederer
    Ann Allen
    Shuying Yang
    European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41 : 743 - 758
  • [9] Eosinophils and Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
    Baloira Villar, Adolfo
    Pallares Sanmartin, Abel
    Nunez Fernandez, Marta
    ARCHIVOS DE BRONCONEUMOLOGIA, 2016, 52 (10): : 541 - 541
  • [10] Inhaled Corticosteroids and Pneumonia in Chronic Obstructive Pulmonary Disease
    Malo de Molina, Rosa
    Restrepo, Marcos I.
    Mortensen, Eric M.
    Izquierdo, Jose L.
    Anzueto, Antonio
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2010, 6 (03) : 162 - 166